Novo Nordisk initiates phase I trial of oral device

A new Novo Nordisk device, which is designed to be swallowed, will soon be tested in a phase I study according to the Clinical Trials database, but the pharmaceutical firm in charge does not want to divulge further details due to a scheduled quiet period.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk is taking another step on its road toward developing new technologies for oral drug delivery.

According to a registration on the Clinical Trials database, the pharmaceutical firm has initiated a phase I trial of a new device dubbed DV3395-C1 for the oral delivery of drugs. Per the description, the study will investigate the safety of the device when it is swallowed by healthy participants.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs